March/April 2022 Issue | Blood Cancers Today

March/April 2022

This issue of Blood Cancers Today explores new goals from the Cancer Moonshot 2.0, a study that demonstrates a decade-long response to CAR T-cell therapy, and more.

Viewpoints

Editor's Message

Back to Normal…Hopefully…Maybe…

Features

News

In the Literature

Adding Navitoclax to Ruxolitinib in Persistent or Progressive Myelofibrosis

Could Single-Agent Blinatumomab Take a BiTE Out of B-Cell ALL?

CARs Take Leukemia Patients Closer to a Cure With Decade-Long Remissions

A New Target for Tisagenlecleucel: Primary Central Nervous System Lymphoma

MRD Negativity Plus Complete Response or Better Associated With Improved PFS in Myeloma

Regulatory Actions

Pacritinib Approved for Patients With Intermediate or High-Risk Myelofibrosis

Immune Checkpoint Inhibitor Blood Test Launches in the United States

FDA Approves Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

US Senate Confirms Robert Califf as FDA Commissioner

FDA Provides Recommendations for Antibody Drug Conjugate Development

State of the Art

The Past, Present, and Future of Venetoclax-Based Therapies in Acute Myeloid Leukemia

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer